Mesenchymal Stromal Cell, Systemic Sclerosis
Conditions
Brief summary
Mesenchymal stromal cells (MSC) are multipotent cells which carry immunomodulatory, pro-angiogenic and anti-fibrotic properties, that can target Systemic Sclerosis (SSc) pathogenesis and its clinical manifestations. The increasing use of MSC, harvested from bone marrow (MSC(M)), adipose tissue (MSC(AT)), or umbilical cord (MSC(UC)) in a variety of indications, provides consistent evidence supporting their safety in humans. The efficacy of MSC(M) intravenous (IV) injection for treating acute graft versus host disease led to their marketing approval in 2012 and MSC(AT) (Alofisel) were approved for severe Crohn's fistula in 2018. MSC represent a promising therapeutic approach for SSc. We previously a) showed disease-specific abnormalities in MSC(M) from SSc patients, providing strong rationale to use allogeneic MSC to treat SSc patients, b) completed the first phase I/II dose escalation trial using allogenic MSC(M) infusion in 20 severe SSc patients (ClinicalTrials.gov: NCT02213705, PHRC AOM 11-250) with no safety issues, significant improvement in skin fibrosis at 3 to 6 months after infusion which appeared lower thereafter, thereby supporting the need for repeated infusions. In vitro, experimental and clinical studies suggest that MSC properties vary according to their tissue of origin/source. We demonstrated that compared to MSC(M), MSC(AT) are easier to harvest and display higher proliferative capability before entering senescence, higher genetic stability, and superior immunosuppressive properties. The objective of the present research is the successful production of allogeneic MSC(AT) derived from selected healthy donors, with adequate phenotypic criteria according to the International Society for Cell & Gene Therapy. Considering the above rationale, these MSC(AT) will subsequently be used in a Phase I/II randomized clinical trial testing allogeneic MSC(AT) systemic infusion for treatment of severe systemic sclerosis.
Interventions
OTHERAdipose tissue harvesting
Adipose tissue harvesting (40-60g) during the abdominal liposuction or lipoaspiration under general anaesthesia which is performed according to usual care
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 18 and ≤ 55 years * BMI \<30 * Non-smoker * Admission for a pre-scheduled plastic surgery intervention liposuction or lipo-aspiration in the abdominal wall under general anesthesia * Written consent * Affiliated to a social security
Exclusion criteria
* Weight \< 50 kg * Positive viral serology : Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Hepatitis E Virus (HEV), syphilis, Human T Lymphotropic virus (HTLV), active infection with IgM+ for toxoplasmosis, Epsiten Barr Virus (EBV), Cytomegalovirus (CMV) * Active generalized infection (viral, parasitic, tuberculosis, leprosy...) * Significant comorbidities according to donor health history or existing risk factors for viral infections within the past 12 months: * Multiple sexual partners between the donor or his or her usual partner * Intravenous addiction to the donor or regular partner * Accident of exposure to blood or derivatives suspected of being contaminated * Uncontrolled hypertension * Human dura mater transplant * Surgical history of the central nervous system * Dementia or neurological disease that may evoke subacute spongiform encephalopathy * Family history as part of subacute spongiform encephalopathy * Hematological malignancies * Active or any past history of cancer * History of chemotherapy or irradiation * Systemic or autoimmune disease * Multiple adenopathy, splenomegaly, hepatomegaly * Icterus * Haemophilia * Known insulin-dependent diabetes * Treatment with extractive pituitary hormones (including growth hormones) * Steroids therapy (for more than 5 days) in the past 3 months * Lithium treatment * Pregnancy * Deprived of freedom
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Production of at least 3 batches of MSC(AT) derived from donors adipose tissue | Up to 2 months |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of viability | Up to 2 months |
| Percentage of CD73+ cells | Up to 2 months |
| Percentage of CD90+ cells | Up to 2 months |
| Percentage of CD105+ cells | Up to 2 months |
| Percentage of expression of HLA-DR | Up to 2 months |
Contacts
Primary ContactDominique Farge, Pr
Backup ContactJérôme Lambert, Dr
Outcome results
None listed